China's CBMG Signs Up GE China to Develop Immunotherapy/Stem Cell Processes

Cellular Biomedicine formed a strategic collaboration with GE Healthcare Life Sciences China to co-develop an automated autologous cell preparation system for immunotherapy/stem cell manufacturing. To develop the processes, the two companies will build a joint laboratory inside CBMG’s new Zhangjiang GMP facility in Shanghai. CBMG developed its own progenitor and dendritic cell therapies for cancer and osteoarthritis. Two years ago, it acquired CAR-T cancer immunotherapy technology from the Chinese PLA 301 Hospital of Beijing. More details... Stock Symbol: (NSDQ: CBMG) Share this with colleagues: // //